Rovaldi Christopher 4
4 · Keros Therapeutics, Inc. · Filed Feb 3, 2022
Insider Transaction Report
Form 4
Rovaldi Christopher
Chief Operating Officer
Transactions
- Award
Employee Stock Option (right to buy)
2022-02-01+100,000→ 100,000 totalExercise: $49.34Exp: 2032-01-31→ Common Stock (100,000 underlying)
Footnotes (1)
- [F1]One-fourth (1/4th) of the shares subject to the option shall vest on February 1, 2023, and one-twelfth (1/12th) of the remaining shares subject to the option shall vest in equal quarterly installments thereafter, subject to the Reporting Person continuing to provide service through each such date.